Citadel Advisors
IMDX

Citadel Advisors’s Insight Molecular Diagnostics IMDX Stock Holding History

Citadel Advisors’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-505
Closed -$2.32K – 14844
2023
Q2 		$2.32K Buy
+505
New +$2.54K ﹤0.01% 13796
2022
Q4 		– Sell
-1,245
Closed -$18K – 15275
2022
Q3 		$18K Sell
1,245
-2,455
-66% -$42.5K ﹤0.01% 12111
2022
Q2 		$67K Sell
3,700
-1,215
-25% -$27.6K ﹤0.01% 11739
2022
Q1 		$146K Sell
4,915
-3,495
-42% -$112K ﹤0.01% 11878
2021
Q4 		$365K Sell
8,410
-265
-3% -$15.2K ﹤0.01% 10472
2021
Q3 		$618K Buy
8,675
+2,075
+31% +$191K ﹤0.01% 9364
2021
Q2 		$758K Sell
6,600
-2,955
-31% -$289K ﹤0.01% 9079
2021
Q1 		$992K Buy
9,555
+3,030
+46% +$288K ﹤0.01% 8122
2020
Q4 		$312K Buy
6,525
+5,815
+819% +$213K ﹤0.01% 9007
2020
Q3 		$20K Buy
+710
New +$20.4K ﹤0.01% 9861

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Citadel Advisors's IMDX Position: Q1 2026 in Review

Citadel Advisors sold out of Insight Molecular Diagnostics (IMDX) in Q1 2026, closing a stake of 15,647 shares — an estimated $117K sold.

Citadel Advisors first reported a position in IMDX in Q1 2018 and held it in 18 quarters. The position peaked at $603K in Q1 2021. 41 funds tracked by Wall St. Rank hold IMDX as of Q1 2026.

  • Citadel Advisors reported no remaining Insight Molecular Diagnostics position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 15,647 Insight Molecular Diagnostics shares in Q1 2026, an estimated $117K.
  • Citadel Advisors first reported a position in Insight Molecular Diagnostics in Q1 2018 and held it in 18 quarters.
  • Citadel Advisors's Insight Molecular Diagnostics position peaked at $603K in Q1 2021.
  • 41 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.